VPRIV Powder for solution for infusion Ref.[9230] Active ingredients: Velaglucerase alfa

Source: European Medicines Agency (EU)  Revision Year: 2020  Publisher: Shire Pharmaceuticals Ireland Limited, Block 2 & 3 Miesian Plaza, 50โ€“58 Baggot Street Lower, Dublin 2, Ireland

Product name and form

VPRIV 400 Units powder for solution for infusion.

Pharmaceutical Form

Powder for solution for infusion.

White to off-white powder.

Qualitative and quantitative composition

One vial contains 400 Units* of velaglucerase alfa**.

After reconstitution, one ml of the solution contains 100 Units of velaglucerase alfa.

* An enzyme unit is defined as the amount of enzyme that is required to convert one micromole of p-nitrophenyl ฮฒ-D-glucopyranoside to p-nitrophenol per minute at 37ยบC.
** produced in an HT-1080 human fibroblast cell line by recombinant DNA technology.

Excipient with known effect: One vial contains 12.15 mg sodium.

For the full list of excipients, see section 6.1

Active Ingredient Description
Velaglucerase alfa

Velaglucerase alfa supplements or replaces beta-glucocerebrosidase, the enzyme that catalyzes the hydrolysis of glucocerebroside to glucose and ceramide in the lysosome, reducing the amount of accumulated glucocerebroside and correcting the pathophysiology of Gaucher disease. Velaglucerase alfa increases haemoglobin concentration and platelet counts and reduces liver and spleen volumes in patients with type 1 Gaucher disease.

List of Excipients

Sucrose
Sodium citrate dihydrate (E331)
Citric acid monohydrate (E330)
Polysorbate 20

Pack sizes and marketing

20 ml vial (type I glass) with a stopper (fluoro-resin coated butyl rubber), one piece seal, and flip-off cap.

Pack sizes of 1, 5 and 25 vials. Not all pack sizes may be marketed.

Marketing authorization holder

Shire Pharmaceuticals Ireland Limited, Block 2 & 3 Miesian Plaza, 50–58 Baggot Street Lower, Dublin 2, Ireland

Marketing authorization dates and numbers

EU/1/10/646/002
EU/1/10/646/005
EU/1/10/646/006

Date of first authorisation: 26 August 2010
Date of latest renewal: 19 June 2015

Drugs

Drug Countries
VPRIV Austria, Brazil, Canada, Cyprus, Estonia, Spain, Finland, France, Ireland, Israel, Japan, Lithuania, Netherlands, New Zealand, Poland, Romania, Turkey, United Kingdom, United States

ยฉ All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.